title: 10-year long-term survival of a metastatic EGFR-mutated nonsmall cell lung cancer patient.
authors.affiliation: Drug Development Dept, Gustave Roussy Cancer Campus, University Paris-Sud, Villejuif, France.
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Kempf
authors.affiliation: Medical Oncology Dept, Gustave Roussy Cancer Campus, Villejuif, France.
authors.forename: David
authors.initials: D
authors.lastname: Planchard
authors.affiliation: Medical Oncology Dept, Gustave Roussy Cancer Campus, Villejuif, France.
authors.forename: Thierry
authors.initials: T
authors.lastname: Le Chevalier
authors.affiliation: Drug Development Dept, Gustave Roussy Cancer Campus, University Paris-Sud, Villejuif, France soria@igr.fr.
authors.forename: Jean-Charles
authors.initials: JC
authors.lastname: Soria
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics* / Q000401:mortality; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D066246:ErbB Receptors / Q000235:genetics*; D000069347:Erlotinib Hydrochloride / Q000008:administration & dosage; D005091:Exons; D005260:Female; D000077156:Gefitinib; D017353:Gene Deletion; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000401:mortality; D008875:Middle Aged; D009154:Mutation; D009362:Neoplasm Metastasis; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011799:Quinazolines / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; C512478:EGFR protein, human; D066246:ErbB Receptors; D011505:Protein-Tyrosine Kinases; D000077156:Gefitinib